Dupilumab in adolescents with moderate to severe atopic dermatitis. a 32-week real-world experience during the COVID-19 pandemic

Real‐life data concerning dupilumab effectiveness and safety in adolescents (≥12 to <18 years) with moderate‐to‐severe atopic dermatitis (AD) are rarely reported.1 In the adolescent phase III randomized, placebo‐controlled, clinical trial (LIBERTY AD ADOL)2 and the phase IIa and subsequent phase III open label extension (LIBERTY AD PED‐OLE)3 dupilumab showed significant signs and symptoms improvement at week‐16, with a good safety profile. Herein, we report our real‐life experience on AD adolescents treated with dupilumab.